R 0008/21 (Petition rejected as clearly inadmissible) of 30.05.2022
- European Case Law Identifier
- ECLI:EP:BA:2022:R000821.20220530
- Date of decision
- 30 May 2022
- Case number
- R 0008/21
- Petition for review of
- T 0777/17 2020-09-22
- Application number
- 09711390.6
- IPC class
- A61P 35/04A61K 38/09A61P 35/00
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Treatment of metastatic stage prostate cancer with degarelix
- Applicant name
- Ferring B.V.
- Opponent name
- Generics (UK) Ltd (trading as Mylan)
- Board
- -
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 112a(2)(c)European Patent Convention Art 112a(2)(d)European Patent Convention Art 113European Patent Convention Art 113(1)European Patent Convention Art 116(1)European Patent Convention R 104European Patent Convention R 106European Patent Convention R 107(1)European Patent Convention R 107(2)European Patent Convention R 109(2)Rules of procedure of the Boards of Appeal 2020 15(2)(c)(ii)Rules of procedure of the Boards of Appeal 2020 15(2)(c)(iv)
- Keywords
- Obligation to raise objections - objection raised (no)
Petition for review - clearly inadmissible - Catchword
- -
- Citing cases
- -
Order
For these reasons it is decided that:
The petition for review is unanimously rejected as being clearly inadmissible.